ReviewFrontiers of medicine2017
Human monoclonal antibodies as candidate therapeutics against emerging viruses.
Review in Frontiers of medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Direct airway delivery of a humanized anti-H7N9 neutralizing antibody broadly protects against divergent H7 influenza viruses in the mouse model.Journal of virology · 2025Article
- Article
- Preparation and characterization of mouse-derived monoclonal antibodies against the hemagglutinin of the H1N1 influenza virus.Virus research · 2024Article
- Efficacy of the combination of BRII-196/BRII-198 in the treatment of COVID-19 vaccine breakthrough infections.American journal of translational research · 2024Article
- A Review on Role of Inflammation in Coronavirus Disease.Endocrine, metabolic & immune disorders drug targets · 2024Review
- The Common Cold and Influenza in Children: To Treat or Not to Treat?Microorganisms · 2023Review
- Review
- Precise location of two novel linear epitopes on the receptor-binding domain surface of MERS-CoV spike protein recognized by two different monoclonal antibodies.International journal of biological macromolecules · 2022Article
- Randomized, placebo-controlled, single-blind phase 1 studies of the safety, tolerability, and pharmacokinetics of BRII-196 and BRII-198, SARS-CoV-2 spike-targeting monoclonal antibodies with an extended half-life in healthy adults.Frontiers in pharmacology · 2022Article
- Generation and utility of a single-chain fragment variable monoclonal antibody platform against a baculovirus expressed recombinant receptor binding domain of SARS-CoV-2 spike protein.Molecular immunology · 2022Article
- SARS-CoV-2 Antiviral Therapy.Clinical microbiology reviews · 2021Review
- A comprehensive review of COVID-19 biology, diagnostics, therapeutics, and disease impacting the central nervous system.Journal of neurovirology · 2021Review
- Discovery of Antivirals Using Phage Display.Viruses · 2021Review
- Potent germline-like monoclonal antibodies: rapid identification of promising candidates for antibody-based antiviral therapy.Antibody therapeutics · 2021Article
- Neutralizing Human Antibodies against Severe Acute Respiratory Syndrome Coronavirus 2 Isolated from a Human Synthetic Fab Phage Display Library.International journal of molecular sciences · 2021Article
- Dissecting strategies to tune the therapeutic potential of SARS-CoV-2-specific monoclonal antibody CR3022.JCI insight · 2021Article
- Targeted Therapy in Cardiovascular Disease: A Precision Therapy Era.Frontiers in pharmacology · 2021Review
- Novel therapeutic approaches for treatment of COVID-19.Journal of molecular medicine (Berlin, Germany) · 2020Review
- Research Progress of Drug Treatment in Novel Coronavirus Pneumonia.AAPS PharmSciTech · 2020Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The emergence of new pathogens, such as severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and Ebola virus, poses serious challenges to global public health and highlights the urgent need for novel antiviral approaches. Monoclonal antibodies (mAbs) have been successfully used to treat various diseases, particularly cancer and immunological disorders. Antigen-specific mAbs have been isolated using several different approaches, including hybridoma, transgenic mice, phage display, yeast display, and single B-cell isolation. Consequently, an increasing number of mAbs, which exhibit high potency against emerging viruses in vitro and in animal models of infection, have been developed. In this paper, we summarize historical trends and recent developments in mAb discovery, compare the advantages and disadvantages of various approaches to mAb production, and discuss the potential use of such strategies for the development of antivirals against emerging diseases. We also review the application of recently developed human mAbs against SARS-CoV, MERS-CoV, and Ebola virus and discuss prospects for the development of mAbs as therapeutic agents against emerging viral diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.